天康生物(002100.SZ)2019年度淨利潤預增91.25%-123.12%
格隆匯1月16日丨天康生物(002100.SZ)公佈,預計2019年度歸屬於上市公司股東的淨利潤6億元-7億元,同比增長91.25%-123.12%。
報告期內,公司新建養殖基地投產後,養殖規模擴大,2019年銷售生豬84.27萬頭,同比增長30.33%;受國內整體生豬產能下降、生豬供給偏緊的影響,生豬銷售價格上漲,公司生豬養殖業務收入及盈利同比大幅上升,全年收入15.01億元,同比增長110.81%。
報告期內,飼料業務銷售規模持續增長,業績增長穩健;製藥業務受非瘟疫情影響,業績有所下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.